VTGN

VistaGen Therapeutics Stock Price

0.8005
-0.0045 (-0.56%)
0.8005
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.0045 -0.56% 0.8005 0.00 0.00 0.00 0.805 09:08:36
Bid Price Ask Price Spread Spread % News
0.82 0.83 0.01 1.2% 1 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
600 315,629 $ 0.8032922 $ 253,542 2,106,263 0.10 - 1.4862
Last Trade Time Type Quantity Stock Price Currency
09:08:34 5 $ 0.829 USD

VistaGen Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 45.94M 56.03M 49.81M $ - $ - -0.50 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 9.00 0.60%

more financials information »

VistaGen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.7771.000.740.86068622,811,7210.02353.02%
1 Month0.52141.000.460.72354672,962,4090.279153.53%
3 Months0.40211.000.350.62878051,860,6150.398499.08%
6 Months0.78881.000.300.6041291,049,3270.01171.48%
1 Year0.601.48620.100.6619954835,0550.200533.42%
3 Years1.892.650.101.11668,790-1.09-57.65%
5 Years11.2514.050.101.16422,915-10.45-92.88%

VistaGen Therapeutics Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.


Your Recent History
NASDAQ
VTGN
VistaGen T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.